Insmed to Present Polycystic Ovary Syndrome Data to American Society for Reproductive Medicine.

Business Editors/Health & Medical Writer

BIOWIRE2K

RICHMOND, Va.--(BW HealthWire)--Oct. 19, 2001

Insmed Incorporated (NASDAQ: INSM) announced today that the results of a recent clinical trial of d-chiro-inositol (INS-1) to treat polycystic ovary syndrome will be presented at the 57th annual meeting of the American Society for Reproductive Medicine in Orlando, Florida on October 24, 2001.

PCOS is a major woman's health disorder that may affect 6-10% of women of reproductive age. It is characterized by physical signs of high levels of male hormones, and the absence of ovulation. Women with this disorder are often overweight, have excess facial hair, acne and menstrual irregularities.

"PCOS is the leading cause of anovulatory infertility in the United States," said John E. Nestler, M.D., Chief of the Division of Endocrinology at the Medical College of Virginia, "and there are no drugs approved to treat it. This study reinforces the value of INS-1 in the care of these women."

When compared to their normal counterparts, women with PCOS have a higher risk of developing endometrial cancer, as well as:

-- A four-fold increase in the risk of developing hypertension;

-- A seven-fold increase in the risk of developing type 2

diabetes; and

-- A seven-fold increase in the risk of having a heart attack.

Insmed's trial was designed to evaluate the incidence of hyperandrogenemic anovulation in women diagnosed with PCOS, and the effects of INS-1 in this population. The results of the trial corroborated the company's previously reported findings, as published in the New England Journal of Medicine (Nestler, J.E., et al. Ovulatory and Metabolic Effects of D-Chiro-Inositol in the Polycystic Ovary Syndrome. N Engl J Med 1999: 340: 1314-20).

Dr. Nestler has published over 60 original scientific publications, over 40 reviews and editorials, and over 60 abstracts involving endocrine disorders. Dr. Nestler also co-authored the book, 'Androgen Excess Disorders in Women,' published in 1997. Dr. Nestler currently serves on the Editorial Boards for The Journal of Clinical Endocrinology and Metabolism and Steroids, and he serves on the Research Affairs Committee of The Endocrine Society.

About Insmed Incorporated

Insmed Incorporated is a biopharmaceutical company focused on the development of pharmaceutical products for the treatment of type 2 diabetes and other metabolic and endocrine disorders associated with insulin resistance. Further information is available at www.insmed.com.

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements regarding expected financial position, results of operations, cash flows, dividends, financing plans, business strategies, operating efficiencies or synergies, budgets, capital and other expenditures, competitive positions, growth opportunities for existing or proposed products or services, plans and objectives of management, demand for new pharmaceutical products, market trends in the pharmaceutical business, inflation and various economic and business trends. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that product candidates may fail in the clinic or may not be successfully marketed, the company may lack financial resources to complete development of product candidates, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release.